KYMR
Kymera Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.75 EPS, $28.8M rev
Last earnings -0.5% on 2026-04-30
$113.51
▲ +3.83%$113.51▲ +157.28%
over 1Y
L $37.68H $116.46
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.8%
1W-2.5%
1M+59.2%
3M+32.9%
YTD+56.0%
1Y+157.3%
Hold
Conviction
Horizon
Long (>12mo)
Street · 30 analysts
Strong Buy
Pre-revenue TPD biotech with a promising oral-degrader pipeline and marquee partners, but deep losses make it a binary, speculative bet.
Revenue $39.2M · FY2025
Kymera is a clinical-stage leader in targeted protein degradation (TPD), aiming to deliver oral small molecules with biologics-like activity in immunology. The scientific and strategic validation is real: lead STAT6 degrader KT-621 has entered the BROADEN2 (atopic dermatitis) and BREADTH (asthma) Phase 2b trials, an oral IRF5 degrader (KT-579) is in Phase 1, and the company has high-profile collaborations with Sanofi (IRAK4 degrader KT-485, advancing to clinical testing in 2026) and Gilead (CDK2 molecular glues announced June 2025). The addressable immunology market is large, and oral convenience versus injectable biologics is a credible differentiator.
The financials, however, are those of a pre-commercial biotech and demand caution. There is no product revenue — the $39.2M of FY2025 revenue is collaboration income and it fell 16.7%. Operating loss widened to -$349M and net loss to -$311M as R&D rose 31.8% to $317M, and the company burned $233M of operating cash. EPS was -$3.69, and the share count grew 25.7% as it raised capital. Since inception Kymera has consumed the bulk of $2.75B raised.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:53 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross profit | — | — | — | — | — |
| Operating income | -$101M | -$161M | -$166M | -$262M | -$349M |
| Net income | -$100M | -$155M | -$147M | -$224M | -$311M |
| Diluted EPS | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| Net margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$8.98B
EV / EBITDA—
EV / Sales229.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-3.3%
FCF yield-2.5%
Quality & risk
ROIC (est.)-17.5%
Free cash flow-$234M
Total debt—
Net cash$357M
Altman Z-Score33.39 safe
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+25.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — agreement terminated (2026-02-26). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-302026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4/APeriod ending 2026-06-262026-07-02open ↗144Filing2026-07-02open ↗144Filing2026-07-01open ↗4Period ending 2026-06-262026-06-30open ↗4Period ending 2026-06-262026-06-30open ↗144Filing2026-06-30open ↗144Filing2026-06-29open ↗144Filing2026-06-29open ↗4Period ending 2026-06-262026-06-26open ↗
Frequently asked
- Is Kymera Therapeutics, Inc. (KYMR) a buy?
- KYMR currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Pre-revenue TPD biotech with a promising oral-degrader pipeline and marquee partners, but deep losses make it a binary, speculative bet.
- What is Kymera Therapeutics, Inc.'s quality score?
- KYMR scores 40.031734123762796/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001815442, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 6/21/2026, 8:53:25 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.